country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-156018

Copy Link Print Information

PI3Kα-IN-13

PI3Kα-IN-13 (Compound 18a) is a PI3Kα inhibitor (IC₅₀: 2.5 nM). PI3Kα-IN-13 induces tumor cell apoptosis. PI3Kα-IN-13 inhibits cancer cell proliferation with IC₅₀s of 0.75 μM (MCF-7), 3.79 μM (HCT-116), 13.71 μM (MDA-MB-231), 9.85 μM (SW620), respectively. PI3Kα-IN-13 inhibits tumor cell colony formation, migration and invasion.

For research use only. We do not sell to patients.

CAS No.: 2955529-67-4
Formula: C₂₁H₁₉N₅O₃
Molecular Weight:389.41

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (266 KB)

PI3Kα-IN-13 Chemical Structure

CAS No.: 2955529-67-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

PI3Kα

All PI3K Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	3.79 μM Compound: 18a	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 37651880]
HCT-116	IC₅₀	7.24 μM Compound: 18a	Antiproliferative activity against human HCT-116 cells expressing PIK3CA with H1047R mutation assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells expressing PIK3CA with H1047R mutation assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 37651880]
MCF-10A	IC₅₀	53.98 μM Compound: 18a	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 37651880]
MCF7	IC₅₀	0.75 μM Compound: 18a	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 37651880]
MCF7	IC₅₀	3.32 μM Compound: 18a	Antiproliferative activity against human MCF7 cells expressing PIK3CA with E545K mutation assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells expressing PIK3CA with E545K mutation assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 37651880]
MDA-MB-231	IC₅₀	13.71 μM Compound: 18a	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 37651880]
NCM460	IC₅₀	49.72 μM Compound: 18a	Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 37651880]
SW-620	IC₅₀	9.85 μM Compound: 18a	Antiproliferative activity against human SW-620 cells assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human SW-620 cells assessed as reduction in cell viability incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 37651880]

Chemical Information

CAS No. 2955529-67-4
Molecular Weight 389.41
Formula C₂₁H₁₉N₅O₃
SMILES

NC1=NC2=CC(C3=CC=C4N=CC(N5C[C@H](OCCO6)[C@H]6C5)=NC4=C3)=CC=C2O1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (266 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zheng XM, et al. Design, synthesis and bioevaluation of PI3Kα-selective inhibitors as potential colorectal cancer drugs. Eur J Med Chem. 2023 Nov 15;260:115754. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Get Quote In-stock